Healthcare and Artificial Intelligence Startups Lead Late October Funding Momentum
Amsterdam, Sunday 25 October 2026
Seven startups secured key investments this week, highlighted by a massive 65 billion won pre-IPO raise for lodging platform The Rest alongside solid backing for digital healthcare pioneers.
Specialised Capital Injections Strengthen Digital Health and Biotechnology
The venture capital market during the fourth week of October 2026—running from 19 to 23 October—illustrated selective capital allocation, with digital health and therapeutic platforms securing notable backing [1]. On 19 October 2026, digital healthcare operator MyBenefit closed a 3 billion won Series A financing round [1]. The round featured strategic and institutional backing from InBody alongside the Sports Industry Fund of Funds under the Korea Sports Promotion Foundation [1]. This transaction pushed MyBenefit’s cumulative capital raised from 4 billion won to 7 billion won [1], representing a cumulative expansion of 75 per cent. MyBenefit previously secured its initial 4 billion won from a consortium including NH Investment & Securities, WE Regional Enterprise Development Fund, Korea Biotechnology Investment, Bogwang Investment, T Investment, and Alpenroot Asset Management [1]. According to Chief Executive Jung Seok-mo, the capital will be deployed to accelerate technological innovation and content enhancement as the company targets expansion in the global healthcare market [1].
Clinical Validation Anchors Early-Stage Medical Technology Rounds
Simultaneously, digital therapeutics developer Olso Care (AllsoCare) completed a 3.42 billion won pre-Series A round on 19 October 2026, led by Daewoong Investment [1]. The injection elevated the startup’s cumulative funding from 0.82 billion won to 4.24 billion won [1], marking an increase of 417.073 per cent. Olso Care focuses on artificial intelligence-driven software targeting musculoskeletal disorders across clinical pathways spanning surgical planning to post-operative home rehabilitation [1]. Kim Jong-ho, Chief Executive of Olso Care, emphasised that receiving confirmatory clinical trial approval from the Ministry of Food and Drug Safety, paired with institutional capital, provides the empirical validation required to set global clinical standards for musculoskeletal medical AI [1]. Beyond digital therapies, non-AI biotechnology firm Trioer demonstrated ongoing investor interest in traditional life sciences by securing a 33 billion won mega-deal to advance two dedicated platforms targeting antibody therapeutics and antibody-drug conjugates (ADCs) [1].
Venture Scale Reaches Core AI Infrastructure and Edge Computing
Artificial intelligence ventures constituted five of the seven deals announced during the period, led by platforms addressing operational deployment costs and edge capabilities [1]. On 21 October 2026, on-device AI startup Traceweave raised a 3 billion won seed financing round at a post-money valuation of 30 billion won [1], meaning incoming investors acquired an equity stake representing 10 per cent of the company. Formed in October 2025 through Antler Korea’s Startup Generator, Traceweave develops edge processing driven by its proprietary ‘Phase-TITAN’ architecture and was selected for the NVIDIA Inception Grand Challenge [1]. Investors backing the round included Mirae Asset Capital, Quad Ventures, Naver D2SF, and Antler Korea, with partners pointing to performance validation with automotive manufacturers as a foundation for broader edge deployment [1].
Overcoming Hardware Bottlenecks and Accelerating Enterprise SaaS Workflows
Addressing enterprise computing infrastructure, software startup AniBridge secured an undisclosed seed investment on 22 October 2026 from The Ventures [1]. AniBridge—co-founded by Korea Advanced Institute of Science and Technology (KAIST) professors Park Jong-se and Kwon Yeong-jin, and advised by Stanford University and SambaNova’s Kunle Olukotun—holds 26 AI system patents and over 110 published academic papers [1]. The company, which won accolades at IISWC 2024 and ISPASS 2026 for its large language model serving simulator, is enrolled in the Ministry of SMEs and Startups’ TIPS programme [1]. AniBridge is scheduling multi-client pilot programmes and a Kakao Cloud proof-of-concept before 31 December 2026, leading to a planned commercial product launch in 2027 [1]. The Ventures Chief Executive Kim Cheol-u and AniBridge Chief Executive Park Jong-se observed that as commercial AI integration expands, cross-hardware orchestration software must evolve to decouple serving costs from single-vendor graphics processing units [1]. Alongside infrastructure, generative media platforms also captured growth capital; AI video developer Nation A closed an 8.5 billion won Series A round on 21 October 2026 backed by Hana Securities, KDB Industrial Bank, Hyundai Investment Partners, and Ilshin Venture Capital, pushing cumulative fundraising from 3.2 billion won to 11.7 billion won [1], an expansion of 265.625 per cent.
Digitalisation of Legacy Assets Culminates in Major Proptech Transaction
While early-stage AI software captured high transaction frequency, the single largest transaction of the week closed on 20 October 2026, when hospitality solutions and proptech firm The Rest (Deuhyuksik) completed a 65 billion won pre-IPO round [1]. Co-led by TS Investment and VIP Asset Management, the round lifted The Rest’s cumulative capital pool from 42.8 billion won to 107.8 billion won [1], a growth rate of 151.869 per cent. The startup manages digital workflows, operational IT, and physical real estate assets in the hotel sector [1]. Executive Director Lee Dae-yeol of TS Investment noted that the company distinguishes itself by directly synthesising proprietary on-site operating data into planning and yield enhancements [1]. The Rest intends to deploy up to 10 billion won by 2027 to expand its footprint in midscale three- and four-star hotels, establishing strategic partnerships with international chains ahead of a planned initial public offering target in 2028 [1].